Notwithstanding promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from pharmacy benefit managers. These companies are frequently creating barriers to coverage, like high price criteria and pr